This study aims to evaluate the diagnostic utility of hypoxia inducible factor 1 subunit alpha (HIF1A) and carbonic anhydrase 9 (CA9) expression in differentiating between the 3 main types of pancreatic cystic neoplasms (PCNs): serous cystic neoplasms (SCNs), mucinous cystic neoplasms (MCNs), and intraductal papillary mucinous neoplasms (IPMNs).
Methods
A retrospective analysis was conducted on 72 surgically resected PCNs (35 SCNs, 23 MCNs, and 14 IPMNs). Immunohistochemical staining for HIF1A and CA9 was performed and scored semi-quantitatively. HIF1A and CA9 mRNA expression levels were also quantified using qRT-PCR. Statistical analyses correlated biomarker expression with detailed clinicopathological features and patient survival.
Results
HIF1A mRNA expression was significantly higher in SCNs compared to MCNs and IPMNs (P < .001). Immunohistochemically, HIF1A protein was detected in 27 SCNs (77%) but was absent in all MCNs and IPMNs. In contrast, CA9 expression was frequently observed across all 3 PCN types (91% of SCNs, 96% of MCNs, and 86% of IPMNs) and showed no significant differential value.
Conclusion
HIF1A expression is a specific immunohistochemical marker for SCNs, reflecting underlying VHL/HIF pathway dysregulation and aiding in their distinction from mucinous PCNs (MCNs and IPMNs). CA9 lacks diagnostic specificity. Incorporating HIF1A assessment into diagnostic algorithms could improve the preoperative classification and management of PCNs.
ReidMDLewisMMWillinqhamFF, et al.The evolving role of pathology in new developments, classification, terminology, and diagnosis of pancreatobiliary neoplasms. Arch Pathol Lab Med. 2017;141(3):366–380.
2.
LennonAMWolfgangC. Cystic neoplasms of the pancreas. J Gastrointest Surg. 2013;17(4):645–653.
3.
AdsayNV. Cystic neoplasia of the pancreas: pathology and biology. J Gastrointest Surg. 2008;12(3):401–404.
4.
YamaoKYanagisawaATakahashiK, et al.Clinicopathological features and prognosis of mucinous cystic neoplasm with ovarian-type stroma: a multi-institutional study of the Japan Pancreas Society. Pancreas. 2011;40(1):67–71.
5.
TanakaMFernandez-Del CastilloCAdsayV, et al.International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology. 2012;12(3):183–197.
6.
LennonAMWolfgangCLCantoMI, et al.The early detection of pancreatic cancer: what will it take to diagnose and treat curable pancreatic neoplasia?. Cancer Res. 2014;74(13):3381–3389.
7.
SahoraKMino-KenudsonMBruggeW, et al.Branch duct intraductal papillary mucinous neoplasms: does cyst size change the tip of the scale? A critical analysis of the revised international consensus guidelines in a large single-institutional series. Ann Surg. 2013;258(3):466–475.
8.
MaxwellPHWiesenerMSChangGW, et al.The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;399(6733):271–275.
9.
IwaiKYamanakaKKamuraT, et al.Identification of the von Hippel-Lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. Proc Natl Acad Sci USA. 1999;96(22):12436–12441.
10.
PérignyMHammelPCorcosO, et al.Pancreatic endocrine microadenomatosis in patients with von Hippel-Lindau disease: characterization by VHL/HIF pathway proteins expression. Am J Surg Pathol. 2009;33(5):739–748.
11.
MoorePSZamboniGBrighentiA, et al.Molecular characterization of pancreatic serous microcystic adenomas: evidence for a tumor suppressor gene on chromosome10q. Am J Pathol. 2001;158(1):317–321.
12.
VortmeyerAOLubenskyIAFogtF, et al.Allelic deletion and mutation of the von Hippel-Lindau (VHL) tumor suppressor gene in pancreatic microcystic adenomas. Am J Pathol. 1997;151(4):951–956.
13.
MatthaeiHSchulickRDHrubanRH, et al.Cystic precursors to invasive pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2011;8(3):141–150.
14.
ReidMDChoiHJMemisB, et al.Serous neoplasms of the pancreas: a clinicopathologic analysis of 193 cases and literature review with new insights on macrocystic and solid variants and critical reappraisal of so-called “serous cystadenocarcinoma”. Am J Surg Pathol. 2015;39(12):1597–1610.
15.
WHO Classification of Tumours Editorial Board. WHO Classification of Tumours: Digestive System Tumours. 5th ed. Vol 1. IARC; 2019.
16.
NoëMNiknafsNFischerCG, et al.Genomic characterization of malignant progression in neoplastic pancreatic cysts. Nat Commun. 2020;11(1):114085.
17.
SinghiADKoayEJChariSTMaitraA. Early detection of pancreatic cancer: opportunities and challenges. Gastroenterology. 2019;156(7):2024–2040.
18.
GriffinJFPageAJSamahaGJ, et al.Patients with a resected pancreatic mucinous cystic neoplasm have a better prognosis than patients with an intraductal papillary mucinous neoplasm: a large single institution series. Pancreatology. 2017;17(3):490–496.
19.
DudejaVAllenPJ. Premalignant cystic neoplasms of the pancreas. Semin Oncol. 2015;42(1):70–85.
20.
DengSFanZGongY, et al.Clinical implication of serum CA125 for the prediction of malignancy in mucinous cystic neoplasms of the pancreas. Exp Ther Med. 2020;20(6):158.
21.
HataTMizumaMMotoiF, et al.Serum anti-p53 antibody can serve as a predictive marker for histological grade of intraductal papillary mucinous neoplasms of the pancreas. Pancreas. 2020;49(6):768–773.
22.
KimSWSongIHAnS, et al.Pancreatic serous cystic neoplasms accompanying other pancreatic tumors. Hum Pathol. 2017;60:104–113.
23.
SatoYMukaiMSasakiM, et al.Intraductal papillary-mucinous neoplasm of the pancreas associated with polycystic liver and kidney disease. Pathol Int. 2009;59(3):201–204.
24.
ChuLCSinghiADHarounRR, et al.The many faces of pancreatic serous cystadenoma: radiologic and pathologic correlation. Diagn Interv Imaging. 2017;98(3):191–202.
25.
PozzessereCCastaños GutiérrezSLCorona-VillalobosCP, et al.Diffusion-weighted magnetic resonance imaging in distinguishing between mucin-producing and serous pancreatic cysts. J Comput Assist Tomogr. 2016;40(4):505–512.
26.
ChenHYDengXYPanY, et al.Pancreatic serous cystic neoplasms and mucinous cystic neoplasms: differential diagnosis by combining imaging features and enhanced CT texture analysis. Front Oncol. 2021;11:745001.
27.
SunYYangSQiE, et al.Comparative diagnostic evaluation with contrast-enhanced ultrasound, computed tomography and magnetic resonance imaging in patients with pancreatic cystic neoplasms. Cancer Manag Res. 2020;12:2889–2898.
28.
TriantopoulouCGourtsoyianniSKarakaxasD, et al.Intraductal papillary mucinous neoplasm of the pancreas: a challenging diagnosis. Diagnostics (Basel). 2023;13(12):2015.
29.
SalviaRBurelliANepiA, et al.Pancreatic cystic neoplasms: still high rates of preoperative misdiagnosis in the guidelines and endoscopic ultrasound era. Surgery. 2023;174(6):1410–1415.
30.
ZhongLChaiNLinghuE, et al.A prospective study on endoscopic ultrasound for the differential diagnosis of serous cystic neoplasms and mucinous cystic neoplasms. BMC Gastroenterol. 2019;19(1):127.
31.
MatthaeiHFeldmannGLingohrP, et al.Molecular diagnostics of pancreatic cysts. Langenbecks Arch Surg. 2013;398(8):1021–1027.
32.
SinghiADNikiforovaMNMcGrathK. DNA testing of pancreatic cyst fluid: is it ready for prime time?. Lancet Gastroenterol Hepatol. 2017;2(1):63–72.
33.
PanicciaAPolancoPMBooneBA, et al.Prospective, multi-institutional, real-time next-generation sequencing of pancreatic cyst fluid reveals diverse genomic alterations that improve the clinical management of pancreatic cysts. Gastroenterology. 2023;164(1):117–133.e7.
34.
WuJMatthaeiHMaitraA, et al.Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med. 2011;3(92):92ra66.
35.
NikiforovaMNKhalidAFasanellaKE, et al.Integration of KRAS testing in the diagnosis of pancreatic cystic lesions: a clinical experience of 618 pancreatic cysts. Mod Pathol. 2013;26(11):1478–1487.
36.
SinghiADNikiforovaMNFasanellaKE, et al.Preoperative GNAS and KRAS testing in the diagnosis of pancreatic mucinous cysts. Clin Cancer Res. 2014;20(16):4381–4389.
37.
AmatoEMolinMDMafficiniA, et al.Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas. J Pathol. 2014;233(3):217–227.
38.
WangYSunYFengJ, et al.Glycopatterns and glycoproteins changes in MCN and SCN: a prospective cohort study. Biomed Res Int. 2019;2019:2871289.
39.
CuiMHuYZhangZ, et al.Cyst fluid glycoproteins accurately distinguishing malignancies of pancreatic cystic neoplasm. Signal Transduct Target Ther. 2023;8(1):406.
